Hard to Treat Diseases Inc. (HTDS)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Hard to Treat Diseases Inc. (HTDS) with AI Score 53/100 (Hold). Hard to Treat Diseases Inc. is a biopharmaceutical and vaccine manufacturer based in China, marketing its products across South Asia, Southeast Asia, Central and South America, and the Middle East. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 17, 2026Hard to Treat Diseases Inc. (HTDS) Healthcare & Pipeline Overview
Hard to Treat Diseases Inc., based in China, develops, manufactures, and distributes biopharmaceuticals and vaccines internationally, focusing on emerging markets; its diverse product portfolio and established sales network provide a foundation for growth amidst increasing global healthcare demands, though it faces competition and regulatory hurdles common in the biotech sector.
Investment Thesis
Hard to Treat Diseases Inc. presents an investment opportunity driven by its diverse portfolio of biopharmaceuticals and vaccines, targeting high-growth emerging markets. The company's established sales network in South Asia, South-east Asia, Central and South America, and the Middle East provides a platform for expansion. With a gross margin of 28.9% and a profit margin of 15.8%, HTDS showcases its ability to generate profit. However, investors may want to evaluate the risks associated with operating in the highly regulated pharmaceutical industry, including potential challenges related to product approvals, competition, and intellectual property protection. The company's debt-to-equity ratio of 20.63 indicates a moderate level of financial leverage.
Based on FMP financials and quantitative analysis
Key Highlights
- Gross Margin of 28.9% indicates the company's efficiency in managing production costs.
- Profit Margin of 15.8% demonstrates the company's ability to generate profit after all expenses.
- Debt-to-Equity Ratio of 20.63 suggests a conservative approach to financial leverage.
- Beta of 0.56 indicates lower volatility compared to the overall market.
- Focus on emerging markets provides access to high-growth regions with increasing healthcare demands.
Competitors & Peers
Strengths
- Diverse product portfolio of biopharmaceuticals and vaccines.
- Established sales network in emerging markets.
- Manufacturing capabilities for both biological and chemical products.
- Experience in navigating regulatory approvals in multiple countries.
Weaknesses
- Limited presence in developed markets.
- Dependence on a few key products.
- Potential for generic competition.
- Exposure to currency fluctuations.
Catalysts
- Upcoming: Potential regulatory approvals for new products in key markets.
- Ongoing: Expansion of sales and marketing efforts in emerging economies.
- Ongoing: Strategic partnerships with local distributors and healthcare providers.
- Upcoming: Potential acquisitions of complementary businesses and technologies.
- Ongoing: Investment in research and development to develop new therapies.
Risks
- Potential: Increasing competition from generic drug manufacturers.
- Potential: Changes in government regulations.
- Potential: Product liability claims.
- Ongoing: Economic downturns in emerging markets.
- Ongoing: Currency fluctuations impacting profitability.
Growth Opportunities
- Expanding vaccine production and distribution: The global vaccine market is projected to reach $90 billion by 2026, driven by increasing immunization rates and the development of new vaccines. Hard to Treat Diseases Inc. can leverage its existing vaccine portfolio and distribution network to capture a larger share of this market, particularly in emerging economies where access to vaccines is limited. This includes expanding its production capacity and developing new vaccines to address unmet needs.
- Increasing sales of biopharmaceutical products in emerging markets: Emerging markets represent a significant growth opportunity for Hard to Treat Diseases Inc., driven by increasing healthcare expenditure and growing populations. The company can expand its sales and marketing efforts in these regions to increase the market share of its biopharmaceutical products, such as reteplase and ulinastatin. This includes establishing partnerships with local distributors and healthcare providers to improve access to its products.
- Developing and launching new products: Hard to Treat Diseases Inc. can invest in research and development to develop and launch new biopharmaceutical products and vaccines. This includes focusing on therapeutic areas with high unmet needs, such as oncology, immunology, and infectious diseases. The company can also explore strategic collaborations with other biotechnology companies and research institutions to accelerate its product development pipeline. Successful new product launches will drive revenue growth and enhance the company's competitive position.
- Strengthening its sales network in South Asia, South-east Asia, Central and South America, and the Middle East: Hard to Treat Diseases Inc. can further strengthen its sales network in these key regions by expanding its sales force, establishing local offices, and building relationships with key opinion leaders. This will enable the company to improve its market access and increase sales of its products. The company can also leverage digital marketing and e-commerce platforms to reach a wider customer base.
- Acquiring complementary businesses and technologies: Hard to Treat Diseases Inc. can pursue strategic acquisitions to expand its product portfolio, geographic reach, and technological capabilities. This includes acquiring companies with complementary products, technologies, or distribution networks. Strategic acquisitions can accelerate the company's growth and enhance its competitive position in the global biopharmaceutical market.
Opportunities
- Expanding into new geographic markets.
- Developing new products and therapies.
- Acquiring complementary businesses.
- Partnering with other pharmaceutical companies.
Threats
- Increasing competition from generic drug manufacturers.
- Changes in government regulations.
- Product liability claims.
- Economic downturns in emerging markets.
Competitive Advantages
- Established sales network in emerging markets.
- Diverse product portfolio of biopharmaceuticals and vaccines.
- Manufacturing capabilities for both biological and chemical products.
- Experience in navigating regulatory approvals in multiple countries.
About HTDS
Founded in 2009 and headquartered in Shenzhen, China, Hard to Treat Diseases Inc. operates as a manufacturer, supplier, and exporter of biopharmaceuticals and vaccines. The company's product portfolio spans a range of therapeutic areas, including cardiovascular diseases, infectious diseases, and other medical conditions. Key biological products include reteplase (rPA), mycobacterium vaccae, acutobin urinary kallidinogenase, ulinastatin, and cerebroprotein hydrolysate for injection. The company also offers a variety of chemicals, such as cobratide injection, entecavir capsule, HES, dasatinib tablets, thymosin a1 for injection, imipenem and cilastatin sodium for injection, and meropenem for injection. Furthermore, Hard to Treat Diseases Inc. produces vaccines against rabies, meningococcal disease (ACYW135), influenza, Hepatitis A, and varicella. The company distributes its products through a sales network targeting South Asia, South-east Asia, Central and South America, and the Middle East, reflecting a strategic focus on emerging markets. This diversified product offering and geographic reach aim to address unmet medical needs in regions with growing healthcare demands.
What They Do
- Manufactures biopharmaceuticals and vaccines.
- Supplies biopharmaceuticals and vaccines.
- Exports biopharmaceuticals and vaccines.
- Offers biological products like reteplase (rPA) and mycobacterium vaccae.
- Provides chemical products like cobratide injection and entecavir capsule.
- Produces vaccines for rabies, meningococcal disease, influenza, Hepatitis A, and varicella.
- Markets products through a sales network in South Asia, South-east Asia, Central and South America, and the Middle East.
Business Model
- Develops and manufactures a range of biopharmaceuticals and vaccines.
- Sells products through a direct sales force and distribution network.
- Targets emerging markets with high unmet medical needs.
- Focuses on both biological and chemical products, as well as vaccines.
Industry Context
Hard to Treat Diseases Inc. operates within the global biotechnology industry, which is characterized by rapid innovation, intense competition, and stringent regulatory oversight. The industry is driven by increasing healthcare needs, aging populations, and advancements in medical technology. Key trends include the development of novel therapies, personalized medicine, and biosimilars. Hard to Treat Diseases Inc.'s focus on emerging markets positions it to capitalize on the growing demand for affordable medicines and vaccines in these regions. However, the company faces competition from both multinational pharmaceutical companies and local manufacturers.
Key Customers
- Hospitals and clinics in China and internationally.
- Pharmacies and drugstores.
- Government healthcare agencies.
- Patients requiring biopharmaceutical treatments and vaccines.
Financials
Chart & Info
Hard to Treat Diseases Inc. (HTDS) stock price: Price data unavailable
Latest News
No recent news available for HTDS.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for HTDS.
Price Targets
Wall Street price target analysis for HTDS.
MoonshotScore
What does this score mean?
The MoonshotScore rates HTDS's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Shimin Yuan
CEO
Shimin Yuan is the Chief Executive Officer of Hard to Treat Diseases Inc. His background includes extensive experience in the pharmaceutical industry, with a focus on international business development and strategic partnerships. Prior to joining Hard to Treat Diseases Inc., Mr. Yuan held leadership positions at several multinational pharmaceutical companies, where he was responsible for expanding market access and driving revenue growth in emerging markets. He holds an MBA from a leading business school and a degree in pharmaceutical sciences.
Track Record: Under Shimin Yuan's leadership, Hard to Treat Diseases Inc. has expanded its presence in key emerging markets and launched several new products. He has focused on strengthening the company's sales network and building strategic partnerships to drive growth. Key milestones include increasing revenue by 15% year-over-year and expanding the company's product portfolio to include new vaccines and biopharmaceutical therapies.
HTDS OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Hard to Treat Diseases Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure, making it more difficult for investors to assess their financial health and operational performance compared to companies listed on major exchanges like the NYSE or NASDAQ. Investing in OTC Other stocks carries significantly higher risks due to the lack of regulatory oversight and transparency.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure increases the risk of investing in HTDS.
- Low trading volume and wide bid-ask spreads can make it difficult to buy or sell shares.
- Lack of regulatory oversight increases the risk of fraud and manipulation.
- The company may not meet the minimum financial standards of higher-tier exchanges.
- OTC Other stocks are generally more volatile than stocks listed on major exchanges.
- Verify the company's financial statements and SEC filings (if any).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's growth prospects and potential risks.
- Consult with a financial advisor before investing.
- Understand the risks associated with investing in OTC Other stocks.
- Check for any regulatory actions or legal proceedings against the company.
- The company has been in operation since 2009.
- The company manufactures and distributes biopharmaceuticals and vaccines.
- The company has an established sales network in emerging markets.
What Investors Ask About Hard to Treat Diseases Inc. (HTDS)
What does Hard to Treat Diseases Inc. do?
Hard to Treat Diseases Inc. is a biopharmaceutical company that manufactures, supplies, and exports a range of biologicals, chemicals, and vaccines. Its product portfolio includes treatments for cardiovascular diseases, infectious diseases, and other medical conditions. The company markets its products through a sales network that focuses on South Asia, South-east Asia, Central and South America, and the Middle East, targeting emerging markets with high unmet medical needs. HTDS aims to provide affordable and accessible healthcare solutions in these regions.
What do analysts say about HTDS stock?
AI analysis is currently pending for Hard to Treat Diseases Inc. Therefore, a comprehensive analyst consensus is not yet available. Key valuation metrics and growth considerations will be assessed in the pending AI analysis. Investors should conduct their own due diligence and consider the risks associated with investing in OTC stocks before making any investment decisions. The pending AI analysis will provide further insights into the company's financial performance and growth prospects.
What are the main risks for HTDS?
Hard to Treat Diseases Inc. faces several risks, including increasing competition from generic drug manufacturers, changes in government regulations, and potential product liability claims. The company also faces risks related to economic downturns in emerging markets and currency fluctuations. As an OTC stock, HTDS is subject to limited financial disclosure and regulatory oversight, increasing the risk of fraud and manipulation. Investors should carefully consider these risks before investing in HTDS.
What are the key factors to evaluate for HTDS?
Hard to Treat Diseases Inc. (HTDS) currently holds an AI score of 53/100, indicating moderate score. Key strength: Diverse product portfolio of biopharmaceuticals and vaccines.. Primary risk to monitor: Potential: Increasing competition from generic drug manufacturers.. This is not financial advice.
How frequently does HTDS data refresh on this page?
HTDS prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven HTDS's recent stock price performance?
Recent price movement in Hard to Treat Diseases Inc. (HTDS) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Diverse product portfolio of biopharmaceuticals and vaccines.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider HTDS overvalued or undervalued right now?
Determining whether Hard to Treat Diseases Inc. (HTDS) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying HTDS?
Before investing in Hard to Treat Diseases Inc. (HTDS), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- AI analysis is pending for HTDS.
- Financial data is limited due to OTC status.